ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 469

Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study

Andrea Cuervo1, M. Victoria Hernández1, Sonia Cabrera1, Jose Inciarte-Mundo1, Julio Ramirez1, Virginia Ruiz-Esquide1, Juan D. Cañete2 and Raimon Sanmarti1, 1Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, 2Rheumatology, Hospital Clinic, Barcelona, Spain

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Immunoglobulin (IG), Infection, Rheumatoid arthritis (RA), rituximab and safety

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Rituximab (RTX) is a biologic therapy approved for the treatment of active rheumatoid arthritis (RA) refractory to tumour necrosis factor antagonists. It causes B cell depletion, with a progressive reduction of the levels of immunoglobulin (Ig) that may be associated with an increased risk of infection. Our objective was to analyse the long-term safety of treatment with RTX in patients with RA and other inflammatory arthritis, and especially the risk of severe infections.

Methods: We made a retrospective descriptive study including patients treated by the Rheumatology Department of a tertiary hospital from June 2006 to December 2013 who had received at least one cycle of treatment with RTX. We analysed: demographic data (age, sex), diagnosis and disease duration, positive rheumatoid factor (RF) or anti-cyclic citrullinated peptide antibodies (anti-CCP); previous biologic treatment; concomitant treatment: disease-modifying antirheumatic drugs (DMARD) and/or concomitant glucocorticoids (GC); number of cycles received; levels of immunoglobulin (Ig) and adverse effects, especially severe infections.

Results: 53 patients were included (85 % female, mean age 58.9 ± 12.9) until December 2013, who received a total of 169 cycles of RTX (mean: 3.3 ± 2.2 cycles/patient) during 7 years. Diagnoses were: RA (75.5 %), overlap syndrome (11.3 %), systemic lupus erythematosus (5.7 %), psoriatic arthritis (3.7 %), seronegative oligoarthritis (1.9 %) and juvenile idiopathic arthritis (1.9 %). Mean disease duration was 15.1 ± 8.4 years, 79.2 % were RF/anti-CCP positive, 67.9 % had received prior biological treatment, 37.7 % had received ≥ 2 or more biologic drugs, 77.3% received concomitant DMARDs (47.2% methotrexate, 30.2 % leflunomide, 11.3% hydroxychloroquine and 3.8 % mycophenolate mofetil) and 79.2% received GC. A progressive, significant decrease in IgG levels (p = 0.018), IgM (p = 0.018) and IgA (0.05), already evident after the first RTX cycle, was observed, although only 13.2% of patients had Ig levels below the normal range. Twenty-five adverse events were reported, of which 19 were considered drug-related: 2 infusion reactions, 2 cases of leukopenia and 15 infections (7 respiratory tract, 5 urinary tract, 1 soft tissue infection, 1 case of bacteremia and 1 septic shock), and 4 of which were considered serious according to medical criteria, although no patient discontinued RTX for those reasons. No opportunistic infection or malignancy was reported. Patients with low Ig levels did not have a greater number of infections than those with normal Ig levels.

Conclusion: After prolonged exposure to RTX, serious adverse events, including infections, were stable over time and multiple treatment courses, and showed a good safety profile, even in patients with reduced Ig levels.


Disclosure:

A. Cuervo,
None;

M. V. Hernández,
None;

S. Cabrera,
None;

J. Inciarte-Mundo,
None;

J. Ramirez,
None;

V. Ruiz-Esquide,
None;

J. D. Cañete,
None;

R. Sanmarti,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-of-rituximab-in-patients-with-chronic-inflammatory-arthritis-seven-year-follow-up-observational-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology